GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Details are as follows: Conference: Piper Sandler 37th Annual Healthcare Conference The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About Altimmune Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedIn Investor Contact: Media Contact: This press release was published by a CLEAR(R) Verified individual.
Date/Time: Wednesday, December 3, 2025 at 2:30 p.m. ET
Follow @AltimmuneInc on X
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Savannah Valade
Real Chemistry
altimmune@realchemistry.com
